8-K: Capricor Therapeutics to File for Full Approval of Deramiocel for Duchenne Muscular Dystrophy Cardiomyopathy

Capricor Therapeutics plans to submit a Biologics License Application (BLA) for deramiocel to treat all patients with Duchenne muscular dystrophy (DMD) cardiomyopathy, supported by existing cardiac and natural history data.

Summary

• Capricor Therapeutics intends to file a Biologics License Application (BLA) for deramiocel to treat Duchenne muscular dystrophy (DMD) cardiomyopathy.
• The BLA will be supported by existing cardiac data from the Phase 2 HOPE-2 and HOPE-2 Open Label Extension (OLE) trials, compared to natural history data.
• The company plans to initiate a rolling submission in October 2024, with full submission expected by the end of 2024.
• Capricor will combine Cohorts A and B of the Phase 3 HOPE-3 clinical trial to serve as a post-approval study for potential label expansion to treat DMD skeletal muscle myopathy.
• The unblinding of Cohort A of the HOPE-3 trial, previously expected in the fourth quarter of 2024, will not occur at this time.
• Deramiocel has received FDA Orphan Drug Designation and Regenerative Medicine Advanced Therapy (RMAT) designation.
• If approved, Capricor would be eligible to receive a Priority Review Voucher (PRV).

Sentiment

Score: 8

Explanation: The document is positive due to the progress towards BLA submission, positive clinical data, and potential for a PRV. However, the delay in unblinding the HOPE-3 trial and the inherent risks of drug development temper the overall sentiment.

Positives

• The BLA filing is supported by robust cardiac data from the HOPE-2 and HOPE-2 OLE trials.
• The FDA has shown a commitment to advancing therapeutics for rare diseases.
• Deramiocel has demonstrated immunomodulatory, anti-fibrotic, and regenerative actions.
• The company has established internal GMP manufacturing to support BLA and commercialization.
• The potential for a Priority Review Voucher (PRV) could provide additional financial benefit.
• The company has a commercialization agreement with Nippon Shinyaku for the US and Japan.

Negatives

• The unblinding of Cohort A of the HOPE-3 trial has been delayed.
• Deramiocel is still an investigational new drug and not yet approved for any indications.
• None of Capricor's exosome-based candidates have been approved for clinical investigation.

Risks

• The BLA submission and approval process may face regulatory hurdles.
• Clinical trial results may not always translate to real-world effectiveness.
• The company's financial outlook is subject to various factors, including regulatory approvals and market conditions.
• There are risks associated with the commercialization of deramiocel, including competition and market acceptance.
• The company's future revenue streams and projections are subject to uncertainty.

Future Outlook

Capricor aims to complete the BLA submission by the end of 2024, with potential PDUFA in the second half of 2025. The company also plans to expand the label for deramiocel to include skeletal muscle myopathy post-approval.

Management Comments

• Linda Marbn, Ph.D., Capricor's CEO, stated that the company is seeking approval for the cardiomyopathy associated with DMD and will look to expand the label for skeletal muscle myopathy post-approval.
• Dr. Marbn believes this is the best path forward to potential approval, allowing them to bring this novel, first-in-class treatment to patients in need in the most expeditious manner.

Industry Context

This announcement is significant as there are currently no approved therapies for DMD cardiomyopathy, which is the leading cause of death in those with Duchenne. Capricor's approach could potentially redefine the standard of care for DMD.

Comparison to Industry Standards

• The company is comparing its results to natural history data from Vanderbilt University Medical Center and Cincinnati Children's Hospital Medical Center, which is a common practice in rare disease drug development.
• The use of a Priority Review Voucher (PRV) is a standard mechanism to incentivize the development of treatments for rare pediatric diseases.
• The company's approach of combining cohorts for post-approval studies is a strategy to expedite the regulatory process and expand the label of the drug.
• Other companies developing therapies for DMD include Sarepta Therapeutics with gene therapies like Elevidys and exon-skipping therapies like Exondys 51, and PTC Therapeutics with Emflaza and Agamree.

Stakeholder Impact

• Shareholders may see a positive impact due to the progress towards regulatory approval and potential revenue streams.
• Patients with DMD and their families may benefit from a potential new treatment option.
• Employees may be impacted by the company's growth and development.
• The company's partners, such as Nippon Shinyaku, may benefit from the commercialization of deramiocel.

Next Steps

• Capricor plans to initiate the rolling submission of the BLA in October 2024.
• The company aims to complete the BLA submission by the end of 2024.
• Capricor will combine Cohorts A and B of the Phase 3 HOPE-3 trial for post-approval label expansion.

Key Dates

Keywords

Deramiocel, Duchenne muscular dystrophy, DMD, cardiomyopathy, Biologics License Application, BLA, cell therapy, FDA, Orphan Drug Designation, RMAT, Priority Review Voucher, HOPE-2, HOPE-3